Fresenius Medical Care: UBS maintains 'buy' rating
(CercleFinance.com) - UBS has reinstated its "buy" rating on the Fresenius Medical Care (FMC) stock, maintaining its target price at 82 euros, which suggests upside potential of 16% for the German medical supply group.
"The dialysis industry is facing headwinds that are more than priced into FMC," the broker believes, adding that "~15x 2019 PE Fresenius Medical is the cheapest it has been since 2010".
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"The dialysis industry is facing headwinds that are more than priced into FMC," the broker believes, adding that "~15x 2019 PE Fresenius Medical is the cheapest it has been since 2010".
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.